BioSpace News Archive

Gemina Laboratories Ltd. is pleased to announce that the Company has engaged Leede Jones Gable Inc., as agent, to offer, on a commercially reasonable best efforts basis, up to 8,334,000 units of the Company at a price of $0.60 per Unit for aggregate gross proceeds of up to $5,000,400.

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the results from the Phase 3 PROpel trial have been published in NEJM Evidence.

Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”).

QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary health organization devoted to a world of longer and healthier lives, to improve the health of San Diego residents and deconstruct barriers to equitable health in our communities.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK.

The latest market analysis report published by Reports and Data, titled ‘Global Horseradish Peroxidase (HRP) Market – Forecast to 2028,’ thoroughly examines the Horseradish Peroxidase (HRP) industry to provide essential data & information for the targeted readers.